Table 2 Frequency of medication usage by progression outcome.
Progression (n = 404) | No progression (n = 11849) | P-value | |
|---|---|---|---|
Medication class | |||
Anticoagulant | 16.20% | 22.70% | P < 0.00001 |
ACE inhibitor | 31.30% | 36.60% | P < 0.00001 |
Beta blocker | 31.60% | 45.10% | P < 0.00001 |
Myelodysplastic syndrome drug | 5.80% | 0.90% | P < 0.00001 |
NSAID | 18.00% | 22.10% | P < 0.00001 |
Proton-pump inhibitor | 27.60% | 43.10% | P < 0.00001 |
Antiplatelet drug | 48.40% | 43.80% | P < 0.00001 |
Estrogen supplement | 1.80% | 1.70% | P = 0.7 |
Folic acid | 15.50% | 20.50% | P < 0.00001 |
Aldosterone receptor antagonist | 7.80% | 10.90% | P < 0.00001 |
Immunomodulator | 4.30% | 9.80% | P < 0.00001 |
Loop diuretic | 20.60% | 28.80% | P < 0.00001 |
Metformin | 7.80% | 11.30% | P < 0.00001 |
Multivitamin | 30.80% | 42.10% | P < 0.00001 |
Opioid | 22.10% | 34.30% | P < 0.00001 |
Rituximab | 1.50% | 1.60% | P = 0.6 |
Statin | 35.30% | 49.70% | P < 0.00001 |
Corticosteroid | 20.80% | 30.20% | P < 0.00001 |
Testosterone supplement | 1.80% | 2.10% | P = 0.2 |
Thyroid replacement | 15.00% | 19.70% | P < 0.00001 |
Vitamin D supplement | 46.40% | 49.60% | P < 0.001 |
